Table 6.

HCLL activity of peripheral blood blasts from patients with acute leukemias

Cell types6-150Lymphocyte adherence6-151
UntreatedOSGPMocarhaginNeuraminidase
KG1a cells (positive control) ++++ ++++ ++++ −  
Biphenotypic leukemia6-153 ++++ ++++ nd −  
AML (M1)6-152 ++++ ++++ ++++ −  
AML (M2)6-155 +++ +++ +++ −  
AML (M4)6-152,6-154 ++++ ++++ ++++ −  
AML (M5)6-152,6-154 ++++ ++++ ++++ −  
ALL (L2, pre-B) ++++ ++++ ++++ − 
Cell types6-150Lymphocyte adherence6-151
UntreatedOSGPMocarhaginNeuraminidase
KG1a cells (positive control) ++++ ++++ ++++ −  
Biphenotypic leukemia6-153 ++++ ++++ nd −  
AML (M1)6-152 ++++ ++++ ++++ −  
AML (M2)6-155 +++ +++ +++ −  
AML (M4)6-152,6-154 ++++ ++++ ++++ −  
AML (M5)6-152,6-154 ++++ ++++ ++++ −  
ALL (L2, pre-B) ++++ ++++ ++++ − 

For all leukemic specimens analyzed, KG1a cell HCLL activity was assessed in parallel to serve as a comparative control. Cytospins of buffer-, OSGP-, mocarhagin- or neuraminidase (Newcastle)-treated blasts or KG1a cells were prepared and underwent Stamper-Woodruff assay as described in “Materials and methods.” Lymphocytes adherent to leukemic cell monolayers were counted by light microscopy using an ocular grid under 100 × magnification (3 fields per slide, 3 slides per experiment, 3 separate experiments). L-selectin dependence lymphocyte adhesion was confirmed in every experiment as described in “Materials and methods.” Note that L-selectin ligand activity in all treated groups was resistant to OSGP and mocarhagin, and sensitive to neuraminidase.

F6-150

All leukemia specimens showed >80% expression of CD34 and of PSGL-1 except as where indicated by footnote symbols

F6-151

Results from Stamper-Woodruff assay are presented as percentage of cytocentrifuged cells with adherent lymphocytes: −, 0 to 10%, +, 11 to 35%, ++, 36 to 60%, +++, 61 to 85%, and ++++, 86 to 100%.

F6-152

Two different specimens of leukemias with these subtypes were evaluated.

F6-153

This leukemia was negative for all histochemical markers and displayed both myeloid (CD13+/CD33+) and B-lymphoid (CD10+/CD19+/TdT+) cell markers; PSGL-1 expression was low (18% PSGL-1+, see below for staining profiles).

F6-155

PSGL-1 expression was low (14% PSGL-1+ blasts).

F6-154

CD34 expression was absent (<5%) on leukemic cells from one of the 2 patients with M4 and one of the 2 patients with M5 as determined by flow cytometry.

nd, not determined

Close Modal

or Create an Account

Close Modal
Close Modal